Adverse Events, Comorbidities, and HIV

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.

Byanyima discusses COVID-19, HIV, and the power of the community response.

Thirty years ago, the NIH legend deftly negotiated between bureaucrats and activists. As part of Trump’s COVID-19 team, can he negotiate between loyalty and truth?

March 19, 2020: Mood disorders and metabolic syndrome; comorbidity burden among women living with HIV; two-year weight gain after switching to integrase; long-term adipose tissue density trends.

Replacing group meetings and public outreach with telehealth consults, Zoom meet-ups, and food/med curbside deliveries are all part of the solutions.

New findings contribute to the indication that people with HIV taking testosterone therapy should be counseled on the cardiovascular risks.

March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.